Scientific and educational activities

SWG meetings held in the past calendar year

EHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and Differences of Myeloid Neoplasms

Dates

November 2–4, 2024


Location

Budapest, Hungary

Chairs

  • Prof Uwe Platzbecker
  • Prof Konstanze Döhner
  • Prof Claire Harrison

Co-chairs

  • Dr Shahram Kordasti
  • Prof Gert Ossenkoppele
  • Prof Jean-Jacques Kiladjian

Meeting goal

To bring together international experts in MDS, MPN, and AML to:

  • Highlight disease intersections and distinctions
  • Promote collaborative learning
  • Update the clinical and research communities on the latest diagnostic and therapeutic developments across myeloid neoplasms

Highlights

  • A unique tri-disease format encouraging cross-disciplinary dialogue.
  • Case-based discussions tackling clinical dilemmas in overlapping disease entities.
  • State-of-the-art presentations on the immune microenvironment, molecular stratification, and treatment innovations.

Audience and attendance

The meeting was attended by haematologists, clinician-scientists, and trainees from across Europe and beyond.

The audience included specialists in MDS, MPN, AML, and general haematology.

Presentations at national and international meetings on behalf of the SWG

ASH Annual Meeting 2024

Date and location

December 7–9, 2024, San Diego Convention Cente.

Goal

Dissemination of ongoing i4MDS immune-monitoring initiative outcomes

Relevant abstracts presented on behalf of i4MDS and the SWG

Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. A Study by i4MDS Consortium

Presenter

Elena Riva et al.

Audience

The audience was the international MDS research community. There was strong interest from translational clinicians and the pharmaceutical industry.

Clinical Relevance of the Integrative Analysis of Gut Microbiome and Metabolomics in Myeloid Neoplasms

Presenter

Alessia Campagna et al.

Relevance

SWG-aligned multiomics study within i4MDS goals

Clinical trials promoted by or involving the SWG

While not a clinical trial itself, the i4MDS consortium’s immune profiling framework has laid the groundwork for future trials aiming to:

  • Stratify MDS patients based on immune signatures
  • Predict response to immunomodulatory therapy (e.g. hypomethylating agents, checkpoint inhibitors)
  • Evaluate flow-cytometry and cytokine markers as response predictors

Translational work promoted by or involving the SWG

  • Immune profiling panels (flow cytometry, cytokine assays) designed specifically for clinical implementation
  • Integration of multiomics and immune data for precision immunotherapy
  • Future plans include clinical validation of an ‘immune score’ for MDS prognosis and treatment planning
Share